RxDoctor Payments Data

Jerome Lastimosa

Gerontology · Glen Burnie, MDNPI 1588316798

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Corcept Therapeutics at 33.7% of the total.

$695in general payments, 2019–2025

Across 17 payments — averaging $40.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$235
  • Sanofi-aventis U.S. LLC$146
  • Dexcom, Inc.$114
  • Novo Nordisk$103
  • AbbVie$25
  • Astellas Pharma US Inc$21
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$695 in reported general payments places this provider in the 70th percentile of 108 gerontology providers in Maryland.

See all gerontology providers in Maryland

Medicare billing

Part B allowed, 2024
$80,566
Medicare patients
334
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$15,980
TrulicityDulaglutide20$7,401
TradjentaLinagliptin18$4,730
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$2,881
Insulin Lispro Kwikpen U-100Insulin Lispro17$1,892
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$644
Insulin Glargine-Yfgn14$588
Metformin Hcl25$417

Paid to pharmacies, not to this prescriber.

Other gerontology in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →